REO 019 is an open-label Phase Ib trial to determine the safety and maximum tolerated dose of REOLYSIN® in combination with bortezomib (VELCADE®) and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one line of therapy. Eighteen patients will receive bortezomib and dexamethasone on days one, eight and fifteen of each twenty-eight day cycle, and intravenous REOLYSIN® on days one, two, eight, nine, fifteen and sixteen. Cycles of therapy will repeat in the absence of disease progression or unacceptable toxicity. The primary objectives are to determine the safety and maximum tolerated dose of the treatment combination, and overall objective response rate. The secondary objectives include objective response rate at escalating doses, and progression-free and overall survival.